<DOC>
	<DOCNO>NCT00807118</DOCNO>
	<brief_summary>Primary objective demonstrate bioequivalence 4 8 mg commercial formulation fast fed condition , bioequivalence formulation E ( 1 ) use Japanese pivotal study commercial formulation 8 mg . Secondary objective ass food effect 8 mg tablet commercial formulation . These objective set get data Japanese regulatory submission .</brief_summary>
	<brief_title>Phase 1 , Single Dose , Crossover Study Determine Bioequivalence Investigate Food Effect</brief_title>
	<detailed_description />
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Japanese healthy male subject Evidence history clinically significant finding screen</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>bioequivalence , food effect</keyword>
</DOC>